0001654954-24-006744.txt : 20240521
0001654954-24-006744.hdr.sgml : 20240521
20240521170050
ACCESSION NUMBER: 0001654954-24-006744
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240517
FILED AS OF DATE: 20240521
DATE AS OF CHANGE: 20240521
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Giordano Christopher Thomas
CENTRAL INDEX KEY: 0001871714
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34600
FILM NUMBER: 24970392
MAIL ADDRESS:
STREET 1: C/O TENAX THERAPEUTICS, INC.
STREET 2: ONE COPLEY PARKWAY, SUITE 490
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
FORMER NAME:
FORMER CONFORMED NAME: Giordano Chrisopher Thomas
DATE OF NAME CHANGE: 20210708
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0000034956
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 262593535
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 GLEN LENNOX DRIVE
STREET 2: SUITE 300
CITY: CHAPEL HILL
STATE: NC
ZIP: 27517
BUSINESS PHONE: 919-855-2100
MAIL ADDRESS:
STREET 1: 101 GLEN LENNOX DRIVE
STREET 2: SUITE 300
CITY: CHAPEL HILL
STATE: NC
ZIP: 27517
FORMER COMPANY:
FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC.
DATE OF NAME CHANGE: 20080703
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: SINEQUANON CORP
DATE OF NAME CHANGE: 19901219
4
1
section16.xml
PRIMARY DOCUMENT
X0508
4
2024-05-17
0000034956
TENAX THERAPEUTICS, INC.
TENX
0001871714
Giordano Christopher Thomas
101 GLEN LENNOX DRIVE. SUITE 300
CHAPEL HILL
NC
27517
true
true
CEO
false
Stock Option (right to buy)
3.549
2024-05-17
4
A
false
437
0.00
A
2034-05-17
Common Stock
437
437
D
Stock Option (right to buy)
992
2032-06-09
Common Stock
125
125
D
Stock Option (right to buy)
3152
2031-07-06
Common Stock
157
157
D
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
These options were previously reported as covering 200,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4,
2023 and January 2, 2024.
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
These options were previously reported as covering 250,000 shares at an exercise price of $1.97 per share, but were adjusted to reflect the stock splits that occurred on January 4,
2023 and January 2, 2024.
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
/s/ S. Halle Vakani, as Attorney-in-Fact
2024-05-21